CSBR CHAMPIONS ONCOLOGY, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 771856 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.7%
TTM net income YoY-137.8%
TTM EPS YoY—
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—
Margins
Gross margin49.8%
Operating margin-1.7%
Net margin-1.8%
FCF margin-10.1%
EBITDA margin0.5%
Returns
ROE-29.8%
ROA-3.5%
ROIC (approx.)—
Asset turnover1.90x
Leverage & solvency
Liabilities / assets86.6%
Debt / equity0.00x
Current ratio1.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income5.04x
Accruals ratio14.0%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 |
|---|---|---|
| Income statement | ||
| Revenue | $59.42M | $56.94M |
| Cost of revenue | $30.90M | $28.39M |
| Gross profit | $28.52M | $28.55M |
| R&D expense | $9.08M | $6.83M |
| SG&A expense | $11.15M | $9.34M |
| Operating income | -$1.14M | $4.55M |
| Pretax income | -$929,000 | $4.63M |
| Income tax | $246,000 | -$75,000 |
| Net income | -$1.18M | $4.70M |
| EBITDA | $260,000 | $6.15M |
| EPS (basic) | -0.08 | 0.34 |
| EPS (diluted) | -0.08 | 0.33 |
| Weighted avg. shares (diluted) | 13.83M | 14.27M |
| Balance sheet | ||
| Cash & equivalents | $4.87M | $9.79M |
| Receivables | $13.18M | $11.20M |
| Current assets | $19.22M | $22.36M |
| PP&E, net | $3.53M | $4.38M |
| Goodwill | $335,000 | $335,000 |
| Total assets | $26.99M | $32.34M |
| Current liabilities | $19.92M | $23.85M |
| Total liabilities | $22.92M | $28.57M |
| Shareholders' equity | $3.94M | $3.77M |
| Shares outstanding | 13.89M | 13.78M |
| Cash flow statement | ||
| Operating cash flow | -$4.47M | $7.39M |
| Capital expenditure | $564,000 | $389,000 |
| Free cash flow | -$5.04M | $7.00M |
| Investing cash flow | -$540,000 | -$389,000 |
| Financing cash flow | $99,000 | $170,000 |
| Depreciation & amortization | $1.40M | $1.60M |
| Stock-based compensation | $1.24M | $654,000 |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.